Based on its analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing allopurinol, the Pharmacovigilance Risk Assessment Committee (PRAC) reached the following conclusions.
In view of the available literature data indicating that, in order to reduce the risk of adverse reactions, allopurinol should be used at low doses (for example 100 mg/day), PRAC concluded that, where this information is absent from the instructions for medical use, appropriate amendments are needed.
Given the available literature data and data from spontaneous reports on the development of aseptic meningitis, which contained information on a close temporal association and positive tests on repeated withdrawal (de-challenge) and/or re-administration (re-challenge), the PRAC considers that a causal relationship between the use of allopurinol and the development of aseptic meningitis is at least possible. The PRAC concluded that appropriate changes should be made to the instructions for medical use of medicinal products containing allopurinol.
In view of the available data on the adverse reaction “Diarrhea” in a significant number of spontaneous reports, PRAC considers that a causal relationship between the oral use of medicinal products containing allopurinol and the occurrence of diarrhea is at least possible. PRAC concluded that the instructions for medical use of medicinal products containing oral forms of allopurinol should be amended accordingly.
The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) agrees with the PRAC scientific conclusions.
CMDh considers that the benefit/risk balance of medicinal products containing allopurinol remains unchanged, taking into account the proposed changes to the instructions for medical use.
Amendments to be included in the relevant sections of the package insert (new text underlined in bold, deleted text struck through).
Section "Posology and method of administration"
Allopurinol (allopurinol) should be used in low doses (100 mg/day) to reduce the risk of adverse reactions and increased only in the case of a negative serum urate test. Particular caution should be exercised in renal impairment.
“Adverse reactions” section
The adverse reaction “Aseptic meningitis” should be added to the section “Nervous system disorders” with the frequency “Not known”.
The adverse reaction “Diarrhea” should be added to the section “Gastrointestinal disorders” with the frequency “Uncommon”.
Перелік лікарських засобів, що містять алопуринол (allopurinol) і дозволені до медичного застосування в Україні (за даними Державного реєстру лікарських засобів України станом на 05.11.2021).
To analyze the published information, the applicant must use the original text available at the linkhttps://www.ema.europa.eu/en/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable/00000095/202012_en.pdf